Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
143 Leser
Artikel bewerten:
(0)

Philips Introduces HeartModel A.I. at ESC Congress 2015

ANDOVER, Massachusetts and LONDON, August 29, 2015 /PRNewswire/ --

Anatomically intelligent ultrasound tool provides reproducible ultrasound results, fast exam times and seamless workflow, yielding diagnostic confidence in cardiac care

Royal Philips (NYSE: PHG, AEX: PHIA) today announced the European debut of HeartModelA.I., a new Anatomically Intelligent Ultrasound (AIUS) tool that brings advanced quantification, automated 3D views and robust reproducibility to echocardiology. Philips' fastest 3D AIUS ultrasound measurement method was unveiled today on its EPIQ 7 ultrasound system, Philips' first ultrasound with Anatomic Intelligence capabilities, during ESC Congress 2015 in London.

(Video: https://www.youtube.com/watch?v=Nx24-L6-K-4 )

(Photo: http://photos.prnewswire.com/prnh/20150825/261054 )

(Photo: http://photos.prnewswire.com/prnh/20150825/261053 )

Using HeartModelA.I., clinicians can quickly, easily and confidently assess disease states, determine treatment, and guide related therapies. In a recent comparison at one hospital, clinicians were able to acquire and analyze the data necessary to calculate the dimensions and volumes of the left atrium and ventricle (LA and LV) between 3 and 6 times faster using 3D measurements and HeartModelA.I. than with conventional 2D measurements and conventional volume and dimensional analysis.[1] With a rich digital database of anatomical structural models and adaptive system technology, HeartModelA.I. has access to advanced clinical information that automatically adapts to variability in patient anatomy. This knowledge-based identification and patient-specific adaptation provides proven quantification of the left ventricle and atrium, and display of routine apical views.

"Conventional echocardiograms can be very time consuming," said Vitor Rocha, CEO, Ultrasound, Philips. "Health systems are constantly looking for solutions to provide the most efficient and effective way to help clinicians make confident diagnosis. By combining AIUS with the power of HeartModelA.I., we're able to deliver technology that helps simplify a complicated exam and makes it more reproducible."

HeartModelA.I. is part of a suite of new tools and technologies available on Philips' EPIQ 7 ultrasound system. The EPIQ 7 system is designed to enhance automation and reproducibility to help address some of the most critical strains on overburdened hospitals and healthcare systems challenged to provide higher quality care at a lower cost. EPIQ 7 is known for its high-image quality, advanced automation and superb ergonomic design.

"Collecting heart measurements in 3D is difficult and time consuming," said Jose Zamorano, MD, FESC, University Hospital Ramón y Cajal in Madrid. "Philips' HeartModelA.I. helps to make collecting critical cardiac ultrasound measurements easier and more reproducible, which will not only enable time savings, but will hopefully extend the adoption of 3D echocardiography exams to more clinicians."

Philips has a rich history of innovations that redefine how care is delivered. Philips first introduced Anatomical Intelligence with the launch of EPIQ in 2013, Philips is continuing to leverage its expertise in this area to pioneer organ models. HeartModelA.I. on the EPIQ 7 ultrasound system will be available in most markets by the end of the year.

To learn more about AIUS and the full suite of Philips innovative ultrasound solutions, please visit: http://www.philips.com/ultrasound. Philips is showcasing its HeartModelA.I. on the EPIQ 7 system at ESC Congress beginning Aug. 29 through Sept. 2. For more information on Philips presence at the ESC Congress 2015, please visit http://www.philips.com/esc and follow the ESCCongress conversation @PhilipsLiveFrom to continue the conversation.

--------------------------------------------------

1. The fastest times were achieved in cases where the clinicians determined that no manual editing of the measurements was necessary. These results may not reflect those achievable at other institutions.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 108,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy-efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at http://www.philips.com/newscenter.

For more information, please contact:

Kathy O'Reilly
Philips Group Communications
Tel: +1-978-659-2638 Mobile: +1-978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly

Sarah Haeger
Philips
Tel: +1-206-920-8726
Email: Sarah.Haeger@philips.com
Twitter: @sarahhaeger


Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.